{"schema_version":"secwatch.filing_event.v1","accession":"0001398733-26-000041","form_type":"8-K","ticker":"AQST","cik":"0001398733","company_name":"Aquestive Therapeutics, Inc.","filed_at":"2026-08-11T20:06:07+00:00","discovered_at":"2026-08-11T20:08:04.396064+00:00","generated_at":"2026-08-11T20:09:00.176544+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Aquestive Q2 revenue up 38% to $13.8M; Anaphylm NDA resubmission on track for Q3 2026","bullets":["Q2 revenue $13.8M vs $10.0M; manufacture/supply $11.9M, license/royalty $1.3M.","Net loss $22.9M ($0.18/sh) includes $11.7M one-time debt extinguishment; ex-item net loss $11.2M.","Non-GAAP adjusted EBITDA loss improved to $5.2M from $9.3M; cash $98.5M at June 30.","Anaphylm PK study met primary endpoints; human factors study improved; NDA resubmission on track for Q3 2026.","FY2026 guidance unchanged: revenue $46-50M, adj. EBITDA loss $35-30M; manufacturing 48M doses vs 37M."],"urls":{"canonical":"https://secwatch.observer/filing/0001398733-26-000041","json":"https://secwatch.observer/filing/0001398733-26-000041.json","markdown":"https://secwatch.observer/filing/0001398733-26-000041.md","text":"https://secwatch.observer/filing/0001398733-26-000041.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1398733/000139873326000041/0001398733-26-000041-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1398733/000139873326000041/aqst-20260811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-11T20:09:00.176544+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}